Modulation of serotonergic neurotransmission by nitric oxide.
Nitric oxide (NO) and serotonin (5-HT) are two neurotransmitters with important roles in neuromodulation and synaptic plasticity. There is substantial evidence for a morphological and functional overlap between these two neurotransmitter systems, in particular the modulation of 5-HT function by NO. Here we demonstrate for the first time the modulation of an identified serotonergic synapse by NO using the synapse between the cerebral giant cell (CGC) and the B4 neuron within the feeding network of the pond snail Lymnaea stagnalis as a model system. Simultaneous electrophysiological recordings from the pre- and postsynaptic neurons show that blocking endogenous NO production in the intact nervous system significantly reduces the B4 response to CGC activity. The blocking effect is frequency dependent and is strongest at low CGC frequencies. Conversely, bath application of the NO donor DEA/NONOate significantly enhances the CGC-B4 synapse. The modulation of the CGC-B4 synapse is mediated by the soluble guanylate cyclase (sGC)/cGMP pathway as demonstrated by the effects of the sGC antagonist 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ). NO modulation of the CGC-B4 synapse can be mimicked in cell culture, where application of 5-HT puffs to isolated B4 neurons simulates synaptic 5-HT release. Bath application of diethylamine NONOate (DEA/NONOate) enhances the 5-HT induced response in the isolated B4 neuron. However, the cell culture experiment provided no evidence for endogenous NO production in either the CGC or B4 neuron suggesting that NO is produced by an alternative source. Thus we conclude that NO modulates the serotonergic CGC-B4 synapse by enhancing the postsynaptic 5-HT response.
Straub
Volko A
VA
Department of Cell Physiology and Pharmacology, University of Leicester, Leicester LE1 9HN, UK. vs64@le.ac.uk
Grant
James
J
O'Shea
Michael
M
Benjamin
Paul R
PR
D000818:Animals; D002478:Cells, Cultured; D004594:Electrophysiology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D019706:Excitatory Postsynaptic Potentials / Q000187:drug effects; D006162:Guanylate Cyclase / Q000037:antagonists & inhibitors; D066298:In Vitro Techniques; D007191:Indazoles / Q000494:pharmacology; D008195:Lymnaea / Q000502:physiology*; D008784:Methysergide / Q000494:pharmacology; D009046:Motor Neurons / Q000502:physiology; D009474:Neurons / Q000502:physiology; D009569:Nitric Oxide / Q000494:pharmacology* / Q000502:physiology*; D052248:Nitric Oxide Synthase Type I / Q000037:antagonists & inhibitors; D018408:Patch-Clamp Techniques; D012701:Serotonin / Q000502:physiology*; D012702:Serotonin Antagonists / Q000494:pharmacology; D013569:Synapses / Q000502:physiology; D009435:Synaptic Transmission / Q000187:drug effects*
D004791:Enzyme Inhibitors; D007191:Indazoles; D012702:Serotonin Antagonists; D009569:Nitric Oxide; D012701:Serotonin; D052248:Nitric Oxide Synthase Type I; D006162:Guanylate Cyclase; C080122:7-nitroindazole; D008784:Methysergide